BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company.
Biotechnology, Pharmaceuticals, Health
2026-03-12 3:00 AM EDT | PreveCeutical Medical Inc.
Cosmo Presents Agenda for AGM 2026
Dublin, Ireland--(Newsfile Corp. - March 12, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam. The agenda includes, among others, the following discussion and voting items: Report of the Board of Directors on the business year 2025 and the ESG achievements Appropri
Healthcare and Hospitals, Health
2026-03-12 1:58 AM EDT | Cosmo Pharmaceuticals N.V.
Psyched Wellness Announces Private Placement for Proceeds of up to C$1,719,306.94
Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is excited to announce that it has entered into a non-binding memorandum of terms (the "Term Sheet") with Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. (together,
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-03-11 8:54 AM EDT | Psyched Wellness Ltd.
Restart Life Highlights Certified Manufacturing Platform to Drive Margin Expansion and Distribution Growth
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide investors with an update on the strategic value of the Holy Crap™ manufacturing facility and its role in supporting scalable growth, margin expansion, and broader market distribution across the Company's functional wellness portfolio. The Holy Crap™ production facility operates under mul
Technology, Biotechnology, Health
2026-03-11 8:00 AM EDT | Restart Life Sciences Corp.
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-11 7:30 AM EDT | Red Light Holland Corp.
TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the use of VIVI Cap™ for passive thermal protection of insulin during summer travel. The paper, titled "Passive Thermal Protection
Technology, Biotechnology, Pharmaceuticals, Health
2026-03-11 7:00 AM EDT | TempraMed Technologies Ltd.
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-10 4:40 PM EDT | Red Light Holland Corp.
Orange Auto Insurance, Inc., subsidiary of HPN Holdings, Inc. Secures Fronting Carrier Partnership to Launch Innovative Auto Insurance Program
Chicago, Illinois--(Newsfile Corp. - March 10, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or the "Company") today announced that its subsidiary Orange Auto Insurance, Inc ("Orange"), a managing general agency focused on delivering technology-driven automobile insurance solutions, has agreed to terms with a highly rated fronting carrier to support the launch of its new auto insurance program. The partnership marks a significant milestone for the company as it prepares to bring its product
2026-03-10 9:00 AM EDT | HPN Holdings, Inc.
Safe Supply Streaming Co Ltd. Achieves U.S. Federal Vendor Registration and Secures Municipal Vendor Approval in Boca Raton, Florida
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply" or the "Company") is pleased to announce that its wholly owned subsidiary, Safety Strips Tech Corp. ("Safety Strips"), has obtained a Unique Entity Identifier ("UEI") through the United States Government's System for Award Management (SAM.gov) and has received approved vendor status with the City of Boca Raton, Florida.
2026-03-10 7:03 AM EDT | Safe Supply Streaming Co Ltd.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week. Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential techn
Biotechnology, Pharmaceuticals, Health
2026-03-09 11:23 AM EDT | Hemostemix Inc.
Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies
Orlando, Florida--(Newsfile Corp. - March 9, 2026) - Adia Nutrition's (OTCQB: ADIA) subsidiary, Adia Med, has launched a complete digital refresh of its online presence. Through a strategic partnership with ZenChange Marketing, Adia Med has relaunched its website with a modern, streamlined design focused on transparency, accessibility, and clear information about its investigational studies. The update makes it easier for families, researchers, and healthcare professionals to explore the orga
Healthcare and Hospitals, Health
2026-03-09 9:38 AM EDT | Adia Nutrition Inc.
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised
Biotechnology, Pharmaceuticals, Health
2026-03-09 3:15 AM EDT | Defence Therapeutics Inc.
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance
Healthcare and Hospitals, Health
2026-03-09 2:00 AM EDT | Cosmo Pharmaceuticals N.V.
Mobile-health Network Solutions and Medpod Sign MOU to Advance AI-Driven, High-Fidelity Global Healthcare
Singapore, Singapore--(Newsfile Corp. - March 6, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, and Medpod Inc., a U.S.-based innovator in high-fidelity telediagnostics software and infrastructure, today announced the signing of a Memorandum of Understanding (MOU) outlining a strategic partnership to jointly expand intelligent, clinically robust healthcare access across global markets. Under the collaborati
2026-03-06 8:52 AM EST | Mobile-health Network Solutions
Tersis Technologies Names Hugo Mijares Chief Architectural Officer, Positioning for Future Infrastructure and Energy Development in Venezuela
Brooksville, Florida--(Newsfile Corp. - March 5, 2026) - Tersis Technologies (OTCID: TERS), a systems-focused energy and infrastructure company advancing regenerative solutions through practical integration, today announced the appointment of Hugo Mijares as Chief Architectural Officer. Mijares is the founder of ONE D+B MIAMI, a multidisciplinary design studio established in 2007 and known for its focus on material exploration, technical rigor, and architectural clarity. He earned his a
Agriculture, Energy, Alternative Energy, Health
2026-03-05 5:57 PM EST | Tersis Technologies Inc.
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market
Burlington, Ontario--(Newsfile Corp. - March 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips. The patent, titled "Nicotine Bilayer Oral Film and Process for Preparation Thereof," has been granted by the Indian Patent Office under Patent Number
2026-03-05 10:08 AM EST | Rapid Dose Therapeutics Corp.
AliMed Launches New Line of Lightweight Hybrid Gel-Foam Positioners Aimed at Improving Safety for Patients and Staff
Dedham, Massachusetts--(Newsfile Corp. - March 5, 2026) - AliMed, LLC, a Massachusetts-based medical device manufacturer and distributor, is introducing its own line of innovative hybrid gel-foam positioners, expanding its broad portfolio of patient positioners. This unique design delivers the benefits of all-gel positioners with up to 50% reduction in weight. These new positioners are being sold under the name AliBlue™ L
Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 10:00 AM EST | AliMed, LLC
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately. Mr. Tsur has served on BioHarvest's Board since 2021 and
Biotechnology, Pharmaceuticals, Health
2026-03-05 7:30 AM EST | BioHarvest Sciences Inc.